Surgical outcomes and prognostic factors of oral cancer associated with betel quid chewing and tobacco smoking in Taiwan

Liu, Shyun Yeu; Lu, Chin-Li; Chiou, Chang Ta; Yen, Ching Yu; Liaw, Gwo An; Chen, Yi Chun; Liu, Yu‐Chi; Chiang, Wei Fan

doi:10.1016/j.oraloncology.2010.01.008

Cited by 54 publications

(52 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinicopathological factors that influence the treatment outcome and likelihood of recurrence are use of tobacco, advanced T stage or stage III-IV disease at diagnosis, including local regional nodal involvement, positive resection margins or the resection margins being very close to the tumour and thickness of tumour ≥7mm (Battoo et al, 2012;Hakeem et al, 2012;Priya et al, 2012;Wang et al, 2012). Patients who are pathologically negative for local regional nodal involvement could present with regional metastasis later due to occult metastasis (Liu et al, 2010). Although adjuvant therapy reduces local recurrence it does not affect the overall recurrence (Battoo et al, 2012;Priya et al, 2012).…”

Section: Recurrencementioning

confidence: 99%

Epidemiology of Oral Cancer in Asia in the Past Decade- An Update (2000-2012)

Rao¹,

Mejía²,

Roberts‐Thomson³

et al. 2013

Asian Pacific Journal of Cancer Prevention

392

256

View full text Add to dashboard Cite

The prevalence of oral cancers (OC) is high in Asian countries, especially in South and Southeast Asia. Asian distinct cultural practices such as betel-quid chewing, and varying patterns of tobacco and alcohol use are important risk factors that predispose to cancer of the oral cavity. The aim of this review is to provide an update on epidemiology of OC between 2000 and 2012. A literature search for this review was conducted on Medline for articles on OC from Asian countries. Some of the articles were also hand searched using Google. High incidence rates were reported from developing nations like India, Pakistan, Bangladesh, Taiwan and Sri Lanka. While an increasing trend has been observed in Pakistan, Taiwan and Thailand, a decreasing trend is seen in Philippines and Sri Lanka. The mean age of occurrence of cancer in different parts of oral cavity is usually between 51-55 years in most countries. The tongue is the leading site among oral cancers in India. The next most common sites in Asian countries include the buccal mucosa and gingiva. The 5 year survival rate has been low for OC, despite improvements in diagnosis and treatment. Tobacco chewing, smoking and alcohol are the main reasons for the increasing incidence rates. Low socioeconomic status and diet low in nutritional value lacking vegetables and fruits contribute towards the risk. In addition, viral infections, such as HPV and poor oral hygiene, are other important risk factors. Hence, it is important to control OC by screening for early diagnosis and controlling tobacco and alcohol use. It is also necessary to have cancer surveillance at the national-level to collect and utilise data for cancer prevention and control programs.

show abstract

Section: Recurrencementioning

confidence: 99%

Epidemiology of Oral Cancer in Asia in the Past Decade- An Update (2000-2012)

Rao¹,

Mejía²,

Roberts‐Thomson³

et al. 2013

Asian Pacific Journal of Cancer Prevention

392

256

View full text Add to dashboard Cite

show abstract

“…In Taiwan, this disease is the fourth most prevalent malignancy in male and the seventh highest in women (2). Despite momentous progress in recent therapeutic approaches, 40% to 50% of patients with OSCC die within 5 years after being diagnosed (3,4). The poor prognosis of OSCC and a low 5-year survival rate of patients are mainly attributed to the fact that most patients present advanced stages of OSCC at the time of diagnosis, suggesting that early detection of the disease is needed to improve the treatment outcome and reduce the growing burden of OSCC (3,4).…”

Section: Introductionmentioning

confidence: 99%

“…Despite momentous progress in recent therapeutic approaches, 40% to 50% of patients with OSCC die within 5 years after being diagnosed (3,4). The poor prognosis of OSCC and a low 5-year survival rate of patients are mainly attributed to the fact that most patients present advanced stages of OSCC at the time of diagnosis, suggesting that early detection of the disease is needed to improve the treatment outcome and reduce the growing burden of OSCC (3,4). Despite increasing numbers of protein biomarkers identified for detection of OSCC (5), most of them are not clinically accessible nor possess sufficient efficacy for early diagnosis of OSCC.…”

Section: Introductionmentioning

confidence: 99%

Salivary Auto-Antibodies as Noninvasive Diagnostic Markers of Oral Cavity Squamous Cell Carcinoma

Chang

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

Background: Oral cavity squamous cell carcinoma (OSCC) is one of the most common cancers worldwide, and its incidence is still increasing. Approximately 50% of patients with OSCC die within 5 years after diagnosis, mostly ascribed to the fact that the majority of patients present advanced stages of OSCC at the time of diagnosis.Methods: To discover salivary biomarkers for ameliorating the detection of OSCC, herein, we developed a multiplexed bead-based platform to simultaneously detect auto-antibodies (auto-Abs) in salivary samples.Results: Compared with healthy individuals, the salivary levels of anti-p53, anti-survivin, anti-Hsp60, and anti-RPLP0 were significantly elevated in patients with OSCC. Noteworthily, the elevated levels of anti-p53, anti-survivin, and anti-Hsp60 were already observed in individuals with oral potentially malignant disorder. Moreover, the salivary levels of anti-p53, anti-survivin, anti-Hsp60, anti-RPLP0, and anti-CK8 were significantly elevated in patients with early-stage OSCC compared with those in healthy individuals. Most importantly, the use of a combined panel of salivary anti-p53, anti-survivin, anti-Hsp60, and anti-RPLP0 largely improves the detection of OSCC.Conclusion: Collectively, our results reveal that the salivary auto-Abs are effective OSCC biomarkers and the four-auto-Ab panel provides a novel and practicable approach for OSCC screening.Impact: This study provides the first evidence for the potential clinical application of salivary auto-Abs in OSCC diagnosis. Cancer Epidemiol Biomarkers Prev; 23(8); 1569-78. Ó2014 AACR.

show abstract

“…In Taiwan, head and neck squamous cell carcinoma (HNSCC) is a highly prevalent malignancy and is associated with the habit and common risk factor of betel nut chewing (1)(2)(3). Clinical therapies for HNSCC patients consist of multiple-modality treatment with surgery, radiation and multi-drug chemotherapy (4,5).…”

Section: Introductionmentioning

confidence: 99%

Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2

Chang

et al. 2012

Oncology Reports

View full text Add to dashboard Cite

Abstract. Human head and neck squamous cell carcinoma (HNSCC) is a major cause of cancer-related death during the last decade due to its related metastasis and poor treatment outcomes. Gefitinib (Iressa), a tyrosine kinase inhibitor has been reported to reduce the metastatic abilities of oral cancer. Previous studies have shown that epigallocatechin gallate (EGCG), a green tea polyphenol, possesses cancer chemopreventive and anticancer activity. However, the mechanisms involved in the suppression of invasion and metastasis of human oral cancer cells following co-incubation with gefitinib and EGCG remain poorly understood. In the present study, we attempted to investigate the synergistic effects of a combined treatment of gefitinib and EGCG in CAL-27 cells in vitro and to elucidate the underlying molecular mechanisms associated with the supression of cell migration and invasion. In the present study, we found that the individual treatments or the combined treatment of gefitinib and EGCG synergistically inhibited the invasion and migration of CAL-27 cells using Transwell invasion and wound-healing scratch assays, respectively. Similarly, gefitinib in combination with EGCG synergistically attenuated enzymatic activity and the protein expression of MMP-2 in CAL-27 cells. Furthermore, individual or combined treatment with EGCG and gefitinib suppressed the protein expression of p-EGFR and the phosphorylated protein levels of ERK, JNK, p38 and AKT and displayed inhibitory effects on metastatic ability of CAL-27 cells. Combined effects of EGCG and gefitinib-altered anti-metastatic actions for related gene expression were observed using DNA microarray analysis. Importantly, EGCG sensitizes CAL-27 cells to gefitinib-suppressed phosphorylation of epidermal growth factor receptor (EGFR in vitro. Taken together, our results suggest that the synergistic suppression of the metastatic ability of CAL-27 cells after EGCG and gefitinib individual or combined treatment are mediated through mitogen-activated protein kinase (MAPK) signaling. Our novel findings provide potential insights into the mechanism involved with synergistic responses of gefitinib and EGCG against the progression of oral cancer.

show abstract

Surgical outcomes and prognostic factors of oral cancer associated with betel quid chewing and tobacco smoking in Taiwan

Cited by 54 publications

References 41 publications

Epidemiology of Oral Cancer in Asia in the Past Decade- An Update (2000-2012)

Epidemiology of Oral Cancer in Asia in the Past Decade- An Update (2000-2012)

Salivary Auto-Antibodies as Noninvasive Diagnostic Markers of Oral Cavity Squamous Cell Carcinoma

Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2

Contact Info

Product

Resources

About